415 related articles for article (PubMed ID: 18794711)
41. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Argüelles-Arias F; Castro-Laria L; Lobatón T; Aguas-Peris M; Rojas-Feria M; Barreiro-de Acosta M; Soto-Escribano P; Calvo-Moya M; Ginard-Vicens D; Chaparro-Sánchez M; Hernández-Durán M; Castro-Senosiain B; Fernández-Villaverde A; García-Sánchez V; Domínguez-Muñoz E; Caunedo-Álvarez A; Herrerías-Gutiérrez JM
Dig Dis Sci; 2013 Oct; 58(10):2949-54. PubMed ID: 23828140
[TBL] [Abstract][Full Text] [Related]
42. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
Vavricka SR; Rogler G; Gantenbein C; Spoerri M; Prinz Vavricka M; Navarini AA; French LE; Safroneeva E; Fournier N; Straumann A; Froehlich F; Fried M; Michetti P; Seibold F; Lakatos PL; Peyrin-Biroulet L; Schoepfer AM
Inflamm Bowel Dis; 2015 Aug; 21(8):1794-800. PubMed ID: 26020601
[TBL] [Abstract][Full Text] [Related]
43. Important cutaneous manifestations of inflammatory bowel disease.
Trost LB; McDonnell JK
Postgrad Med J; 2005 Sep; 81(959):580-5. PubMed ID: 16143688
[TBL] [Abstract][Full Text] [Related]
44. Concomitant Pyoderma Gangrenosum and Erythema Nodosum in a Patient With Ulcerative Colitis.
Kikuchi N; Matsumura N; Hiraiwa T; Kato Y; Satoh M; Yamamoto T
Actas Dermosifiliogr; 2016 Dec; 107(10):870-872. PubMed ID: 27474109
[No Abstract] [Full Text] [Related]
45. [Cutaneous manifestations in inflammatory bowel disease].
Chavez-Álvarez S; Gómez-Flores M; Ocampo-Candiani J
Gac Med Mex; 2016; 152(5):622-630. PubMed ID: 27792697
[TBL] [Abstract][Full Text] [Related]
46. Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease.
Funayama Y; Kumagai E; Takahashi K; Fukushima K; Sasaki I
Dis Colon Rectum; 2009 Feb; 52(2):311-4. PubMed ID: 19279428
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of pyoderma gangrenosum and Sweet´s syndrome in inflammatory bowel disease at a tertiary healthcare center.
Giraudo F; Miraglia E; Garbi ML; Yantorno M; Maradeo MR; Correa GJ; Tufare F
Rev Esp Enferm Dig; 2021 Oct; 113(10):691-697. PubMed ID: 33267595
[TBL] [Abstract][Full Text] [Related]
48. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis.
Scheinfeld N
Dermatol Online J; 2013 Jun; 19(6):18558. PubMed ID: 24011308
[TBL] [Abstract][Full Text] [Related]
49. Osteoporosis and other extraintestinal symptoms and complications of inflammatory bowel diseases.
Reinshagen M; von Tirpitz C
Dig Dis; 2003; 21(2):138-45. PubMed ID: 14571111
[No Abstract] [Full Text] [Related]
50. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of cytapheresis for induction therapy and extra-intestinal skin manifestations of ulcerative colitis.
Shibuya T; Nomura O; Nomura K; Haraikawa M; Haga K; Ishikawa D; Osada T; Yamaji K; Ikeda S; Nagahara A
Ther Apher Dial; 2022 Jun; 26(3):522-528. PubMed ID: 35247233
[TBL] [Abstract][Full Text] [Related]
52. Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease.
Schorr-Lesnick B; Brandt LJ
Am J Gastroenterol; 1988 Mar; 83(3):216-23. PubMed ID: 3278591
[TBL] [Abstract][Full Text] [Related]
53. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
54. [Immune-mediated inflammatory diseases in patients with inflammatory bowel disease. Baseline data from the Aquiles study].
Marín-Jiménez I; García Sánchez V; Gisbert JP; Lázaro Pérez Calle J; Luján M; Gordillo Ábalos J; Tabernero S; Juliá B; Romero C; Cea-Calvo L; García-Vicuña R; Vanaclocha F
Gastroenterol Hepatol; 2014 Nov; 37(9):495-502. PubMed ID: 24717523
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.
Karmiris K; Avgerinos A; Tavernaraki A; Zeglinas C; Karatzas P; Koukouratos T; Oikonomou KA; Kostas A; Zampeli E; Papadopoulos V; Theodoropoulou A; Viazis N; Polymeros D; Michopoulos S; Bamias G; Kapsoritakis A; Karamanolis DG; Mantzaris GJ; Tzathas C; Koutroubakis IE
J Crohns Colitis; 2016 Apr; 10(4):429-36. PubMed ID: 26721936
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous vasculitis, hypersensitivity vasculitis, erythema nodosum, and pyoderma gangrenosum.
Calabrese LH
Curr Opin Rheumatol; 1991 Feb; 3(1):23-7. PubMed ID: 2043448
[TBL] [Abstract][Full Text] [Related]
57. [Chronic inflammatory bowel diseases. Dermatoses and joint pain can be the initial symptoms].
Stiefelhagen P
MMW Fortschr Med; 2003 Apr; 145(17):14. PubMed ID: 12808794
[No Abstract] [Full Text] [Related]
58. Review article: skin complications associated with inflammatory bowel disease.
Tavarela Veloso F
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():50-3. PubMed ID: 15352894
[TBL] [Abstract][Full Text] [Related]
59. Pyoderma gangrenosum at multiple sites in a post-colostomy ulcerative colitis patient with chronic hepatitis B virus: A case report.
Wang B; Liu T; Liu F; He YL
Int Wound J; 2020 Feb; 17(1):187-190. PubMed ID: 31663272
[TBL] [Abstract][Full Text] [Related]
60. Mapping the relationships between inflammatory bowel disease and comorbid diagnoses to identify disease associations.
Waljee AK; Noureldin M; Berinstein JA; Cohen-Mekelburg SA; Wallace BI; Cushing KC; Hanauer DA; Keeney-Bonthrone TP; Nallamothu B; Higgins PDR
Eur J Gastroenterol Hepatol; 2020 Oct; 32(10):1341-1347. PubMed ID: 32804850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
